quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:12·158d
SECFiling
Tourmaline Bio Inc. logo

SEC Form EFFECT filed by Tourmaline Bio Inc.

TRML· Tourmaline Bio Inc.
Health Care
Original source

Companies

  • TRML
    Tourmaline Bio Inc.
    Health Care

Recent analyst ratings

  • Apr 23UpdateChardan Capital Markets$70.00
  • Mar 6UpdateWedbush$42.00
  • Dec 6UpdateBMO Capital Markets$50.00
  • Nov 11UpdateH.C. Wainwright$49.00
  • Dec 15UpdateJefferies$41.00
  • Dec 4UpdateH.C. Wainwright$48.00

Related

  • SEC158d
    SEC Form EFFECT filed by Tourmaline Bio Inc.
  • SEC160d
    Amendment: SEC Form SCHEDULE 13G/A filed by Tourmaline Bio Inc.
  • SEC167d
    SEC Form 15-12G filed by Tourmaline Bio Inc.
  • INSIDER177d
    SEC Form 4 filed by Director Siegall Clay B
  • INSIDER177d
    Director Mcdade Mark closing all direct ownership in the company (SEC Form 4)
  • INSIDER177d
    Director Kantoff Aaron closing all direct ownership in the company (SEC Form 4)
  • INSIDER177d
    Director Thiara Parvinder closing all direct ownership in the company (SEC Form 4)
  • INSIDER177d
    Director Castelein Caley closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022